TurboCAR Technology Allows a Programmable Cytokine Signaling to Potentially Control T Cell Exhaustion and Improve Function and Potency of AlloCAR T™ Cells
Phase 1 IGNITE Trial Expected to Begin in Mid-2021
ALLO-605 is One of Allogene’s Three Strategies to Target BCMA for the Treatment of Patients with Multiple Myeloma
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.